THIS WEEK
The FDA approved a new oral GLP-1 pill on April 1 with no food or water restrictions, a meaningful mechanistic departure from oral semaglutide that most coverage has glossed over. We break down the ATTAIN trial data and what the head-to-head comparison with oral semaglutide actually shows. On the compounding front, the FDA announced on April 15 that seven peptides including BPC-157, TB-500, KPV, MOTS-c, Semax, Epithalon, and DSIP will go before its advisory panel in July for review. This is not an approval. It is the beginning of a process that typically takes 6 to 12 months after committee review to reach a final FDA decision. The Regulatory Radar section this week covers exactly what that distinction means and what readers with active prescriptions should know right now.
The First Oral GLP-1 With No Food or Water Restrictions
Orforglipron (Foundayo) — FDA Approved April 1, 2026
On April 1, 2026, the FDA approved orforglipron under the brand name Foundayo for adults with obesity or overweight with at least one weight-related comorbidity. It is the first oral GLP-1 receptor agonist that can be taken at any time of day without food or water restrictions. That single sentence contains a mechanistic distinction worth understanding before you read the trial numbers.
The ATTAIN Phase 3 program enrolled more than 4,500 participants across two registration trials. ATTAIN-1 enrolled 3,127 adults without diabetes. At 72 weeks, weight loss was 7.5% at the lowest studied dose, 9.3% at the mid dose, and 11.2% at the highest dose, compared to 2.1% in the placebo group. ATTAIN-2 enrolled 1,613 adults with type 2 diabetes. Weight reductions ranged from 5.1% to 9.6% versus 2.5% in the placebo group, with significant improvements in HbA1c across all doses.
These numbers are meaningful but they are not the headline. Oral semaglutide, approved in December 2025 under the brand Wegovy oral, produces comparable weight loss in the 14% to 15% range at its maximum dose. The more important difference is pharmacological: orforglipron is a small molecule, not a peptide. That distinction is what drives the no-food-restriction advantage and it is covered in full in Mechanism Corner this week.
The safety profile includes the standard GLP-1 gastrointestinal effects: nausea, constipation, diarrhea, vomiting. Orforglipron carries a boxed warning for potential thyroid C-cell tumors, consistent with the class. The higher dose showed GI discontinuation rates of up to 9.7% in the ACHIEVE-3 head-to-head trial, compared to 4.9% with oral semaglutide 14 mg. That tradeoff is real and matters for the clinical decision.
The bottom line on orforglipron: it works, it is FDA approved, and the no-food-restriction advantage is pharmacologically genuine rather than a marketing claim. It is not more effective than injectable GLP-1s or tirzepatide. It occupies a real niche for patients who want an oral option without the absorption constraints of semaglutide tablets. The access pricing is notable: as low as $25 per month with commercial insurance savings card, $149 per month self-pay at the lowest dose, and $50 per month for eligible Medicare Part D patients beginning July 1, 2026.
Full premium section continues with the ACHIEVE-3 head-to-head trial data versus oral semaglutide, dose-by-dose weight loss breakdown, tolerability comparison, and how to think about this approval in the context of the broader oral GLP-1 market.
ACHIEVE-3: The Head-to-Head Against Oral Semaglutide
The ACHIEVE-3 trial is the only published head-to-head comparison of two oral GLP-1 receptor agonists. It compared orforglipron 36 mg against oral semaglutide 14 mg in adults with type 2 diabetes on metformin. Orforglipron 36 mg reduced HbA1c by 2.2% versus 1.4% for oral semaglutide 14 mg. Weight reduction was 19.7 pounds with orforglipron compared to 11.0 pounds with oral semaglutide. Additional improvements in lipids, systolic blood pressure, and triglycerides were seen in both arms, with orforglipron numerically superior across most cardiometabolic endpoints.
GI discontinuation rates were 9.7% with orforglipron versus 4.9% with oral semaglutide. Mean pulse increases were also higher with orforglipron. These are not trivial differences for a patient population where GI tolerability is already the primary reason for discontinuation across the GLP-1 class.
Dose-by-Dose Breakdown from ATTAIN-1 (no diabetes, n=3,127, 72 weeks)
6 mg: 7.5% weight loss vs 2.1% placebo. 12 mg: 9.3% weight loss vs 2.1% placebo. 36 mg: 11.2% weight loss vs 2.1% placebo. Improvements in waist circumference, blood pressure, and lipids were dose-dependent across all groups.
Dose-by-Dose Breakdown from ATTAIN-2 (type 2 diabetes, n=1,613, 72 weeks)
3 mg: 5.1% weight loss vs 2.5% placebo. 12 mg: 7.9% weight loss vs 2.5% placebo. 36 mg: 9.6% weight loss vs 2.5% placebo. HbA1c reductions were significant across all doses. More than 65% of participants taking the highest dose achieved an HbA1c at or below 6.5%.
Approved Tablet Strengths and Pricing
Orforglipron is available as oral tablets at six strengths: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg. Note that trial dose nomenclature differs from approved tablet strengths: confirm current prescribing information for the dose titration schedule before initiating. Eligible patients with commercial insurance may pay as little as $25 per month with a Lilly savings card. Self-pay pricing starts at $149 per month for the lowest dose. Medicare Part D patients may access the drug for $50 per month beginning July 1, 2026.
What This Approval Does Not Tell You
Orforglipron has not been compared head-to-head with injectable semaglutide or tirzepatide. Based on available data, it does not compete on raw weight loss numbers with the injectable class or with tirzepatide specifically. The SUMMIT cardiovascular outcomes trial is ongoing and no cardiovascular benefit has been demonstrated yet. The thyroid C-cell tumor boxed warning is class-wide and does not reflect a specific orforglipron safety signal beyond the class risk.
Oral vs Oral: What the Orforglipron vs Semaglutide Head-to-Head Data Actually Shows
This section is available to premium subscribers. Subscribe to access the full newsletter and all premium content.
Why Orforglipron Works Without an Empty Stomach: Small Molecule vs Peptide GLP-1 Agonism
This section is available to premium subscribers. Subscribe to access the full newsletter and all premium content.
The FDA Is Reviewing Seven Peptides in July. Here Is What That Actually Means.
This section is available to premium subscribers. Subscribe to access the full newsletter and all premium content.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use